Wave Life Sciences (WVE) Forward P/S Multiple

wavelifesciences.com (WVE) - corporate logo

Diversified routes and laboratory contracts guarantee the continuity of nucleotide supplies for Wave Life Sciences (WVE). Capitalization relies on royalties from pharma behemoths for Huntington's disease and Duchenne muscular dystrophy therapies. An in-house cGMP-standard plant ensures the stable production of RNA drugs. The forward P/S history demonstrates sales valuation dynamics, where the current parameter equals 8.70, which helps in analyzing liquidity risks.

wavelifesciences.com - WVE Market Cap to Expected Sales Ratio (period 07/04/2022 - 11/13/2026)

Wave Pharma - analytical breakdowns and key metrics (WVE)

- market price and analyst price targets:
Price Chart Wave Life Sciences Ltd.|WVE - Analyst Median Target
- market capitalization details:
Market Capitalization Wave Pharma|WVE - Real Price to Acquire Entire Company
- issuer book value statistics:
Book Value per Share Wave Life Sciences|WVE - Book Valuation of Business|Market Capitalization to Book Value Ratio wavelifesciences.com|WVE - Company Assets
- debt level and financial liquidity data:
Debt to Equity Wave Life Sciences|WVE - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Wave Life Sciences|WVE - Company Total Debt|Debts to Book Capitalization Wave Pharma|WVE - Long-Term Debt|Company Short-Term Debt Wave Life Sciences|Quick Liquidity Indicator wavelifesciences.com
- financial results and valuation multiples details:
WVE - Net Income|Future Profit Wave Life Sciences|WVE - Price to Earnings Ratio|Forward P/E Multiple Wave Life Sciences Corp|WVE - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple Wave Pharma|WVE - Operating profit before amortization|Earnings per share for the last twelve months Wave Life Sciences|WVE - Earnings per share for the last 12 months|Quarterly EPS earnings growth wavelifesciences.com|WVE - Earnings growth in current year|Expected earnings per share growth for next year Wave Life Sciences
- sales volume and revenue indicators:
WVE - Company Sales|Projected Sales Volume Wave Life Sciences Ltd.|WVE - P/S Multiple|Forward Price-to-Revenue Multiple Wave Pharma
Analysis of all company metrics:Wave Life Sciences Ltd. WVE
Original product of Wave Pharma

A defensive portfolio requires strict asset screening through the lens of future value. The forward P/S of Wave Life Sciences (WVE) compares current market capitalization with expected revenue for the following year to identify business overvaluation. For Wave Life Sciences (WVE), this ratio reflects market expectations regarding the monetization of proprietary RNA technologies and stable demand for therapy. The forward P/S dynamics of Wave Life Sciences (WVE) allow for an assessment of the issuer's valuation stability relative to sales growth rates.

Competitor analysis

Price-to-Projected Revenue Ratio Tempus AI, Inc. TEM|Market Cap to Expected Sales Ratio Qiagen NV (QGEN)|Ionis Pharma - Forward P/S Multiple|Repligen Inc. (RGEN) - Forward Price-to-Revenue Multiple|RNA: Forward P/S Multiple|CRSP - Market Cap to Expected Sales Ratio|WGS (GeneDx) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Ultragenyx Pharmaceutical Inc. RARE|Price-to-Projected Revenue Ratio Beam Therapeutics Corp (BEAM)|Sarepta Corp - Market Cap to Projected Revenue|Forward P/S Multiple TWST (Twist Bioscience)|TXG - Forward Price-to-Revenue Multiple|Intellia Therapeutics, Inc. - Forward P/S Multiple|Market Cap to Future Revenue Ratio Stoke Therapeutics Inc|BioLife Corp (BLFS) - Price-to-Projected Revenue Ratio|MAZE - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple SION|Forward Price-to-Revenue Multiple primemedicine.com (PRME)|Forward Price-to-Revenue Multiple TSHA (Taysha Gene Therapies, Inc.)|Price-to-Projected Revenue Ratio QURE (uniQure NV)|Forward P/S Multiple MGTX (MeiraGTx PLC)|REGENXBIO Corp (RGNX) - Market Cap to Future Revenue Ratio|Solid Biosciences Inc. - Forward P/S Multiple|OCGN (ocugen.com) - Market Cap to Projected Revenue|PacBio (PACB) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue BNTC|DSGN (Design Pharma) - Forward P/S Multiple|Forward P/S Multiple Rocket Corp|Forward Price-to-Revenue Multiple FDMT (4D Molecular Therapeutics)|Forward Price-to-Revenue Multiple lexeotx.com LXEO|Forward P/S Multiple KRRO (Korro Bio)|Forward P/S Multiple Editas Medicine Inc EDIT|SLN: Forward Price-to-Revenue Multiple|PRQR: Price-to-Projected Revenue Ratio|CDXS: Forward P/S Multiple|Market Cap to Future Revenue Ratio sangamo.com (SGMO)|Forward Price-to-Revenue Multiple NAUT|MGX: Forward Price to Sales|Price-to-Projected Revenue Ratio Precision BioSciences, Inc. (DTIL)|Price-to-Projected Revenue Ratio GBIO (generationbio.com)|Forward P/S Multiple BOLD (Boundless Bio, Inc.)|Market Cap to Expected Sales Ratio Exicure Inc. (XCUR)|Celsion Corporation - Forward P/S Multiple|Future Price to Revenue PHIO|MBIO: Forward P/S Multiple|Market Cap to Future Revenue Ratio TransCode Therapeutics, Inc. (RNAZ)|Forward Price-to-Revenue Multiple BNGO|APDN: Forward Price to Sales|Price-to-Projected Revenue Ratio bluebird bio (BLUE)|Market Cap to Expected Sales Ratio immunoprecise.com|Forward P/S Multiple OMGA (Omega)|OMIC - Forward Price-to-Revenue Multiple|Regulus Therapeutics - Forward P/S Multiple|Market Cap to Expected Sales Ratio syros.com SYRS|TBIO: Forward P/S Multiple|Market Cap to Future Revenue Ratio TRACON Pharmaceuticals Inc. (TCON)|Price-to-Projected Revenue Ratio Unity Bio